Leukemia with active central nervous system (CNS) involvement
Active central nervous system (CNS) involvement by leukemia
Evidence of leukemic meningitis or other central nervous system (CNS) involvement by leukemia
Have active central nervous system (CNS) leukemia
Participants with known central nervous system (CNS) leukemia involvement should be excluded from this clinical trial; patients with a history of CNS leukemia that has been treated and is no longer active as judged by the treating investigator are eligible
Active central nervous system (CNS) leukemia
Active central nervous system (CNS) involvement with leukemia
Active, uncontrolled central nervous system (CNS) disease including CNS leukemia
Presence of active untreated central nervous system (CNS) leukemia
Active, uncontrolled central nervous system (CNS) leukemia involvement
Patients with active central nervous system (CNS) leukemia eligible at the discretion of treating physician
Active central nervous system (CNS) or testicular involvement by leukemia
Patients with active, uncontrolled central nervous system (CNS) leukemia will not be eligible
Active central nervous system (CNS) leukemia at time of treatment
Patients with current evidence of active central nervous system (CNS) leukemia
If prior central nervous system (CNS) leukemia, it must be treated and in CNS CR
Symptomatic and refractory central nervous system (CNS) leukemia
Active leukemia in the central nervous system (CNS)
Patients must not have active central nervous system leukemia; patients with history of central nervous system (CNS) leukemia with no evidence of active CNS disease may be enrolled; maintenance intrathecal chemotherapy for adequately treated CNS involvement with leukemia is allowed with approval from the study supporter
History of plasma cell leukemia or MM central nervous system (CNS) involvement
Active and/or untreated central nervous system (CNS) leukemia
Clinical evidence of active central nervous system (CNS) leukemia requiring active therapy; prior CNS leukemia well-controlled by ongoing therapy is allowed
Active central nervous system (CNS) leukemia
No evidence of extramedullary leukemia, such as central nervous system (CNS) or soft tissue involvement
Presence of leukemia in the central nervous system (CNS)
Have active central nervous system (CNS) leukemia
Presence of leukemia in the central nervous system (CNS)
Active central nervous system (CNS) leukemia at time of HCT
Evidence of active extramedullary disease (including central nervous system [CNS] leukemia)
Active central nervous system (CNS) leukemia at time of HSCT
Clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia
Has central nervous system (CNS) involvement of leukemia or a history of CNS leukemia
History of plasma cell leukemia or central nervous system (CNS) involvement
Have clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia.
Subjects must not have evidence of active leukemia in the central nervous system (CNS)
Active central nervous system (CNS) leukemia
Active or suspicion of central nervous system (CNS) leukemia
Proven Central Nervous System (CNS) leukemia
Evidence of active central nervous system (CNS) leukemia
Patients with active/uncontrolled central nervous system (CNS) leukemia
Active central nervous system (CNS) leukemia or known CNS leukemia.
No active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permitted
Central nervous system (CNS) leukemia
Active central nervous system (CNS) involvement with leukemia
Any past or current Central Nervous System (CNS) involvement, including leptomeningeal leukemia.
Clinical evidence of active central nervous system (CNS) leukemia
Subjects with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia.
Active central nervous system (CNS) leukemia
Presence of leukemia in the central nervous system (CNS)
Patients with active and/or untreated central nervous system (CNS) leukemia will not be eligible
Active or prior central nervous system (CNS) leukemia, unless in complete remission for at least  months
Active central nervous system (CNS) leukemia at time of treatment
Active central nervous system (CNS) leukemia
Active, symptomatic central nervous system (CNS) leukemia;
Active central nervous system (CNS) leukemia
Presence of central nervous system (CNS) leukemia.
If prior central nervous system (CNS) leukemia, it must be treated and in CNS complete remission (CR)
Current evidence of central nervous system (CNS) leukemia
For participants with leukemia, has overt central nervous system (CNS) disease (CNS  status).
If prior central nervous system (CNS) leukemia, it must be treated and have no evidence of CNS disease
No active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permitted
No active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permitted
Active central nervous system (CNS) leukemia
Clinical evidence of central nervous system (CNS) or pulmonary leukostasis, or CNS leukemia
Clinical suspicion of active central nervous system (CNS) involvement by leukemia
Has presence of central nervous system (CNS) involvement of leukemia or a history of CNS leukemia
Patients with active central nervous system leukemia are excluded from this clinical trial; patients with a history of central nervous system (CNS) leukemia but no active disease at the time of enrollment are eligible; the absence of CNS disease must be confirmed by flow cytometric and cytologic examination of the cerebrospinal fluid (CSF) within  days of study enrollment
